Respiratory Flashcards

1
Q

Types of lung cancer

A

Small cell vs NSCLC
NSCLC:
- Squamous most common
- Adeno - classically nonsmoker
- Large
Small cell often metastatic at presentation, almost all smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Small cell lung cancer management

A
  • Few surgical options given usually presents with advanced disease
  • Therefore chemo+/-immunotherapy
  • Some evidence for prophylactic cranial irradiation
  • Small cell often produces polypeptide hormones e.g. ACTH
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Lung cancer pathology options

A
  • Sputum cytology (very low sens, better w central lesions)
  • VATS
  • Bronchoscopy + direct or EBUS. EBUS better for staging as lesion + nodes can be accessed
  • Transthoracic needle asp.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Lung cancer central vs peripheral lesions

A

Central - squamous, small, large
Peripheral - Adeno

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

eGFR mutation in lung cancer relevance

A
  • Site for targeted TK targeted therapy
  • More likely positive in low/no smoking pts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ECOG performance status

A

Eastern Coop Onc group
0 - Fully active
5 - deceased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

VATS indications

A

Wedge resection (good for benign lesions e.g. aspergillus)
Bullectomy
Lung biopsy
Recurrent PTx
Lobectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

VATS vs thoracotomy scars

A

Thoracotomy:
- Large (15-20cm) lateral chest wall scar
- Possibly drain scar also
VATS
- 3 scars that triangulate
- 3-6cm scar on lateral wall largest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Benefits of VATS over thoracotomy

A

Smaller incision -> reduced healing time, bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Lobectomy indications

A

Lung cancer
Aspergilloma
TB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Lobectomy/pneumonectomy workup

A

PFTs inc transfer factor and exercise testing.
FEV1 >1.5L for lobectomy, >2L for pneumonectomy
VO2 max >15ml/kg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Respiratory causes of clubbing

A
  • Lung cancer
  • Chronic suppurative conditions - bronchiectasis, abscess, CF
  • Interstitial lung disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Signs to distinguish lobectomy from pneumonectomy

A

Pneumonectomy:
- trachea deviated
- unilateral reduced expansion
- dull hemothorax
- absent tactile fremitus beneath the scar
- Bronchial breathing in upper zones may be present
Lobectomy:
- Trachea central if old
- Lower - dull lower zone with abs breath sounds
- Upper - Hyper-resonant upper zone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Single lung transplant indications

A

“Dry lung”
- COPD
- Fibrosis

COPD biggest indication for transplant worldwide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Double lung transplant indications

A

“Wet lung”
- CF
- Bronchiectasis
- Pulmonary hypertension
(or ILD/COPD - prognosis better for double lung for all indications)

COPD biggest indication for transplant worldwide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

VATS indications resp

A
  • Lung resection (wedge/lobe/segment)
  • Bullectomy
  • Pleural drainage/pleurodesis
  • Diagnostic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

PTx management

A

Asymptomatic - nothing
High risk features - chest drain if >2cm
Symptomatic, no HRF, sufficient size - aspirate, drain or conservative

Persistent >24-48h? Recurrent? Consider pleurodesis/pleurectomy

18
Q

PTx high risk features

A
  • Sig desat
  • HD instab
  • Bilat
  • Underlying lung disease
  • Haemoptx
19
Q

Asthma chronic management

A

1- AIR therapy - anti-inflammatory reliever (formoterol/ICS) PRN
2 - MART - same inhaler regular
3 - MART higher dose
4 - Ref to specialist or LTRA (montelukast) or LAMA (e.g. tiotropium)

20
Q

Role of FeNO in asthma diagnosis

A
  • FeNO = Fraction exhaled nitric oxide
  • NO in parts per billion
  • Raised NO demonstrates airway inflammation as inflammatory cytokines induce NO synthase. NO has a role in negative feedback of bronchoconstriction
  • > 50ppb supportive of asthma dx
21
Q

Asthma investigation

A

(Progress if each step normal)
1 - Eosinophils or FeNO
2 - Spirometry (FEV1:FVC<0.7) with reversibility
3 - PEFR diary with variability (>20%)
4 - Bronchial challenge

22
Q

BTS asthma spirometry results

A
  • Reversibility PEFR 12% and FEV1 200ml more than baseline
23
Q

Basal pulmonary fibrosis causes

A
  • ILD
  • Asbestosis
  • Connective tissue diseases (RA, scleroderma, systemic sclerosis, IBD)
  • Drugs - bleomycin, nitrofurantoin, amiodarone. (MTX now considered unlikely to cause fibrosis)
  • Chronic aspiration
24
Q

Apical pulmonary fibrosis causes

A
  • TB
  • Hypersensitivity pneumonitis aka extrinsic allergic alveolitis (e.g. birds) / ABPA late stage
  • Coal miners pneumoconiosis -> progresses to progressive massive fibrosis
  • Silicosis -> progressive massive fibrosis
  • Ank spond
  • Sarcoidosis
25
Q

Pulmonary fibrosis causative drugs

A
  • Nitrofurantoin
  • Bleomycin
  • Amiodarone
  • Sulfasalazine
26
Q

Fibrosis PFTs

A
  • Reduced FEV1, Reduced FVC, preserved FEV1/FVC (>0.8)
  • Reduced transfer factor (TLCO, KCO)
27
Q

IPF management

A
  • Nintedanib / pirfenidone if PVC <80% - antifibrotics
  • Lifestyle - stop smoking
  • Consider referral for transplant
  • ACP - median survival 2-5 years

+ Supportive:
- Symptom management
- Oxygen
- Treat exacerbations
- PT/OT/resp CNS

28
Q

IPF investigations

A

Bedside:
- PFTs
- ABG (T1RF, T2 in end stage)
- Obs

Bloods:
- CRP, ESR
- ANA & RF positive in some
- anti-CCP and myositis panel suggestive of alternative to IPF

Imaging:
- CXR
- HRCT most important

Special:
- Consider BAL/biopsy if unclear diagnosis

29
Q

What is NSIP

A

Non specific interstitial pneumonia
- Idiopathic interstitial lung disease
- Predominant ground glass > honeycombing on CT
- Therefore more responsive to antiinflammatories - steroids, then DMARDs e.g. MMF

30
Q

What is cryptogenic organising pneumonia

A

ILD affecting peripheral alveoli/bronchioles
Often caused by drugs, infection, RA
Pred usually used to treat

31
Q

Causes of EAA/HP

A

Microorganisms:
- Actinomycetes (bacteria)- farmer’s lung
- Aspergillus (this is not ABPA)
Animal proteins:
- Bird fancier’s lung
- Large farm animals
Occupational:
- Metalworking fluid
- Epoxy resins
- Spray paints

Presents with fevers/chills as well as resp symptoms.
Not IgE so not wheezy

32
Q

ILD lung transplant indications

A

Refer for consideration when:
UIP/IPF & fibrotic forms of NSIP should be referred regardless of lung function (i.e. at diagnosis) if fit enough.

Others referred when FVC<80% or O2 req

33
Q

Cystic fibrosis genetics

A

CFTR gene (cystic fibrosis transmembrane conductance regulator). Autosomal recessive.

Most common = delta F508 gene

34
Q

Cystic fibrosis important bacteria

A
  • Pseudomonas most common in adults
  • (S aureus in childhood)
  • Burkholderia & mycobacterium abscessus contraindication to transplant, and poor prognostic indicator
35
Q

Extrapulmonary cystic fibrosis

A
  • Pancreatic insufficiency -> poor absorption fat soluble vitamins, diabetes
  • Chronic liver disease
  • Hypersplenism
  • Osteoporosis and fractures
  • Gall stones
  • Kidney stones
  • Subfertility. Absence vas deferens in males
  • Constipation and distal intestinal obstruction syndrome
36
Q

CF most common presentation

A
  • Screening on heel prick in infancy
  • Followed by genetic testing & sweat test
37
Q

CF medical therapies

A

Respiratory:
- Nebulised Abx
- Prophylactic Abx
- Nebulised hypertonic saline and mucolytics (DNase)
- CFTR modulators - e.g. ivacaftor, often in combination e.g. Trikafta

38
Q

Leading cause of death post lung transplant

A

Bronchiolitis obliterans - chronic rejection. Usually terminal event.
20% 1 year mortality.

39
Q

Lung transplant immunosuppression

A
  • Tacrolimus
  • MMF
  • Steroids
    in combination
40
Q

Lung transplant contraindications

A

Loads!
- Recent malignancy <5y
- Poor PS / comorbidities
- Certain infections e.g. Burkholderia and Mycobacterium abscessus
- Smoking
- BMI >35 or <17
- Poor treatment adherence

41
Q

Transudate vs exudate effusion

A

Protein <25g/L = transudate, >35g/L = exudate

Between - lights criteria:
- Pleural/serum protein >0.5
- Pleural/serum LDH >0.6
- Pleural LDH >2/3 ULN serum LDH
Any one = exudative

42
Q

Empyema effusion findings

A
  • pH <7.2
  • Frank pus